All Oncology News

Investigators Take Stock of New Landscape for Metastatic HER2-Positive Breast Cancer

November 26th 2020

Breast cancer specialists discuss noteworthy data on efficacy and safety about fam-trastuzumab deruxtecan-nxki, neratinib, and tucatinib.

Selinexor Improves PFS in Advanced Unresectable Dedifferentiated Liposarcoma

November 25th 2020

Selinexor demonstrated a statistically significant improvement in progression-free survival compared with matching placebo in patients with advanced unresectable dedifferentiated liposarcoma, following at least 2 prior treatments.

Atezolizumab/Bevacizumab Lays the Groundwork for Optimal Sequencing in HCC

November 25th 2020

Milind Javle, MD, provides insight into the current treatment paradigm of advanced HCC and the potential influence ongoing research regarding biomarkers of response and novel combinations could have on the field.

SIENDO Trial of Selinexor in Endometrial Cancer Gets Green Light to Continue

November 25th 2020

The phase 3 SIENDO study, which is evaluating maintenance selinexor in endometrial cancer, has been recommended by the Data and Safety Monitoring Board to continue as previously planned without the need to add additional patients to the trial or amend the study protocol, following a prespecified interim futility analysis.

Ruxolitinib Is Linked With High Spleen Responses in IPSS Low-Risk Myelofibrosis

November 25th 2020

November 25, 2020 — Ruxolitinib, when administered earlier on in the treatment course, led to high spleen response rates in patients with low-risk International Prognostic Scoring System myelofibrosis.

Idasanutlin Promotes Transient Expansion of TP53-Mutant Subclones in Polycythemia Vera

November 25th 2020

November 25, 2020 - The oral MDM2 antagonist idasanutlin was found to promote expansion of TP53-mutant subclones among patients with polycythemia vera.

Panelists Parse Out Answers to Key Questions in Hematologic Malignancies

November 25th 2020

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

New Strategies Enhance Care in mUC

November 25th 2020

November 25, 2020 — Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several multidisciplinary advances in the past few years.

Nivolumab Approved in Europe for Advanced Esophageal Cancer

November 24th 2020

November 24, 2020 - The European Commission has approved nivolumab for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma following prior fluoropyrimidine- and platinum-based combination chemotherapy.

CAR T-Cell Therapy Creates Opportunities for Individualized Treatment in MCL

November 24th 2020

Alan P. Z. Skarbnik, MD, highlights how treatment decisions in mantle cell lymphoma have become more nuanced since the FDA approval of the CAR T-cell therapy brexucabtagene autoleucel in the relapsed/refractory setting.